Petros Pharmaceuticals, Inc. (PTPI)
- Previous Close
0.6400 - Open
0.6277 - Bid 0.5801 x 100
- Ask 0.6599 x 100
- Day's Range
0.6100 - 0.6350 - 52 Week Range
0.6020 - 5.2400 - Volume
156,007 - Avg. Volume
637,662 - Market Cap (intraday)
4.242M - Beta (5Y Monthly) 2.45
- PE Ratio (TTM)
-- - EPS (TTM)
-6.3500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.00
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.
www.petrospharma.com21
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: PTPI
Performance Overview: PTPI
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PTPI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PTPI
Valuation Measures
Market Cap
4.24M
Enterprise Value
-409.71k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.23
Price/Book (mrq)
0.35
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-140.20%
Return on Assets (ttm)
-20.32%
Return on Equity (ttm)
-55.95%
Revenue (ttm)
5.82M
Net Income Avi to Common (ttm)
-13.81M
Diluted EPS (ttm)
-6.3500
Balance Sheet and Cash Flow
Total Cash (mrq)
13.34M
Total Debt/Equity (mrq)
66.32%
Levered Free Cash Flow (ttm)
-1.39M
Research Analysis: PTPI
Company Insights: PTPI
PTPI does not have Company Insights